Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Core Insights - Actinium Pharmaceuticals is advancing its clinical programs for Actimab-A, Iomab-ACT, and Iomab-B, with significant regulatory updates and financial results reported for Q3 2024 [1][2][6] Regulatory and Development Updates - Actinium has aligned with the FDA on a seamless Phase 2/3 trial for Actimab-A combined with CLAG-M for relapsed/refractory acute myeloid leukemia (r/r AML) [1][3] - Actimab-A has been selected for the National Cancer Institute's myeloMATCH precision medicine program targeting AML and myelodysplastic syndromes [1][4] - The FDA has cleared two IND applications for Iomab-ACT, including a commercial CAR-T trial and a sickle cell transplant trial, with proof-of-concept data expected in 2025 [1][4] - Actinium is seeking a U.S. strategic partner for Iomab-B to conduct a Phase 3 trial based on FDA guidance [1][5] Financial Performance - As of September 30, 2024, Actinium reported cash and cash equivalents of approximately $78.6 million, expected to fund operations into 2027 [1][6] - Research and development expenses decreased to$9.8 million in Q3 2024 from $11.6 million in Q3 2023, primarily due to lower CMC expenses [7] - General and administrative expenses increased slightly to$2.8 million in Q3 2024, attributed to higher non-cash stock compensation [8] - The net loss for Q3 2024 was $11.6 million, a decrease from$13.3 million in Q3 2023, due to lower R&D expenses [11]